Wei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Zhang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Qingjuan Liu
Key Laboratory of Kidney Diseases of Hebei Province, Department of Pathology, Center of Metabolic Diseases and Cancer Research, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang 050017, China
4 shared publications - Shuxia Liu
Key Laboratory of Kidney Diseases of Hebei Province, Department of Pathology, Center of Metabolic Diseases and Cancer Research, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang 050017, China
4 shared publications - Jinxi Liu
Key Laboratory of Kidney Diseases of Hebei Province, Department of Pathology, Center of Metabolic Diseases and Cancer Research, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang 050017, China
3 shared publications - Xiaojuan Feng
Key Laboratory of Kidney Diseases of Hebei Province, Department of Pathology, Center of Metabolic Diseases and Cancer Research, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang 050017, China
3 shared publications - Xinyan Miao
Key Laboratory of Kidney Diseases of Hebei Province, Department of Pathology, Center of Metabolic Diseases and Cancer Research, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang 050017, China
3 shared publications - Yuexin Tian
Key Laboratory of Kidney Diseases of Hebei Province, Department of Pathology, Center of Metabolic Diseases and Cancer Research, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang 050017, China
3 shared publications
Latest Publications
- Open Access
CRM1-Dependent Cytoplasmic Accumulation of TRIM27 Is Associated with Glomerular Endothelial Cell Injury in Lupus Nephritis
Protein function is closely tied to subcellular localization. Tripartite motif-containing 27 (TRIM27), a member of the tripartite motif family, has been implicated in lupus nephritis (LN), yet the mechanistic basis of its pathogenic role remains incompletely understood. We previously observed that TRIM27 overexpression affects glomerular endothelial cell (GEC) injury and that TRIM27 redistributes from the nucleus to the cytoplasm in LN-affected GECs. Here, using human renal glomerular endothelial cells (HRGECs) and MRL/lpr mice, we show that cytoplasmic TRIM27 may contribute to GEC damage. Mechanistically, TRIM27 appears to translocate to the cytoplasm through association with chromosome region maintenance 1 (CRM1), and this interaction may be promoted by putative phosphorylation at Ser493. Suppression of this phosphorylation reduces the TRIM27–CRM1 association and alleviates GEC injury. Furthermore, we found that protein kinase B (AKT) may act upstream of this process and that cytoplasmic TRIM27 may contribute to forkhead box protein O1 (FOXO1) ubiquitination and degradation, which may, in turn, lead to endothelial injury. Collectively, our findings suggest a pathway in which PI3K-dependent phosphorylation of TRIM27 is coupled to CRM1-mediated cytoplasmic accumulation, with AKT likely contributing to this process, and this cascade may lead to FOXO1 degradation and GEC damage in LN. This study provides new insights into the subcellular regulation of TRIM27 and identifies potential intervention points for mitigating glomerular injury.
Open AccessCRM1-Dependent Cytoplasmic Accumulation of TRIM27 Is Associated with Glomerular Endothelial Cell Injury in Lupus Nephritis
Protein function is closely tied to subcellular localization. Tripartite motif-containing 27 (TRIM27), a member of the tripartite motif family, has been implicated in lupus nephritis (LN), yet the mechanistic basis of its pathogenic role remains incompletely understood. We previously observed that TRIM27 overexpression affects glomerular endothelial cell (GEC) injury and that TRIM27 redistributes from the nucleus to the cytoplasm in LN-affected GECs. Here, using human renal glomerular endothelial cells (HRGECs) and MRL/lpr mice, we show that cytoplasmic TRIM27 may contribute to GEC damage. Mechanistically, TRIM27 appears to translocate to the cytoplasm through association with chromosome region maintenance 1 (CRM1), and this interaction may be promoted by putative phosphorylation at Ser493. Suppression of this phosphorylation reduces the TRIM27–CRM1 association and alleviates GEC injury. Furthermore, we found that protein kinase B (AKT) may act upstream of this process and that cytoplasmic TRIM27 may contribute to forkhead box protein O1 (FOXO1) ubiquitination and degradation, which may, in turn, lead to endothelial injury. Collectively, our findings suggest a pathway in which PI3K-dependent phosphorylation of TRIM27 is coupled to CRM1-mediated cytoplasmic accumulation, with AKT likely contributing to this process, and this cascade may lead to FOXO1 degradation and GEC damage in LN. This study provides new insights into the subcellular regulation of TRIM27 and identifies potential intervention points for mitigating glomerular injury.
- Open Access
BPIFA2 Promotes Renal Fibrosis by Regulating Tubular Epithelial-to-Mesenchymal Transition and Macrophage Activation in Chronic Kidney Disease
Tubulointerstitial fibrosis (TIF) represents the final common pathway leading to end-stage renal disease (ESRD) in chronic kidney disease (CKD). Despite fibrosis being well established as a key pathological hallmark, the molecular mediators that drive this process remain incompletely understood. BPI fold-containing family A member 2 (BPIFA2), a secreted innate immune protein of the sPLUNC family, was upregulated in renal tubular epithelial cells across diverse CKD etiologies and strongly correlated with collagen I accumulation and TIF severity. Tubule-specific knockdown of BPIFA2 significantly alleviated renal histopathological injury and fibrosis, whereas exogenous BPIFA2 administration aggravated fibrotic progression. Mechanistically, BPIFA2 promoted epithelial–mesenchymal transition (EMT) in tubular epithelial cells and triggered macrophage-to-myofibroblast transition (MMT) associated with the TGF-β/Smad3 signaling pathway. In conclusion, our findings identify BPIFA2 as a novel profibrotic mediator in CKD. Targeting BPIFA2 or its downstream signaling may offer new therapeutic opportunities for chronic kidney disease.
Open AccessBPIFA2 Promotes Renal Fibrosis by Regulating Tubular Epithelial-to-Mesenchymal Transition and Macrophage Activation in Chronic Kidney Disease
Tubulointerstitial fibrosis (TIF) represents the final common pathway leading to end-stage renal disease (ESRD) in chronic kidney disease (CKD). Despite fibrosis being well established as a key pathological hallmark, the molecular mediators that drive this process remain incompletely understood. BPI fold-containing family A member 2 (BPIFA2), a secreted innate immune protein of the sPLUNC family, was upregulated in renal tubular epithelial cells across diverse CKD etiologies and strongly correlated with collagen I accumulation and TIF severity. Tubule-specific knockdown of BPIFA2 significantly alleviated renal histopathological injury and fibrosis, whereas exogenous BPIFA2 administration aggravated fibrotic progression. Mechanistically, BPIFA2 promoted epithelial–mesenchymal transition (EMT) in tubular epithelial cells and triggered macrophage-to-myofibroblast transition (MMT) associated with the TGF-β/Smad3 signaling pathway. In conclusion, our findings identify BPIFA2 as a novel profibrotic mediator in CKD. Targeting BPIFA2 or its downstream signaling may offer new therapeutic opportunities for chronic kidney disease.
- Open Access
The CDO1–ACSM3 Axis Mediates Renal Tubule Lipid Deposition and Injury by Causing Mitochondrial Dysfunction in Lupus Nephritis
Renal tubular injury plays a critical role in the progression of lupus nephritis (LN); however, the underlying mechanisms remain poorly understood. In this study, we found that CDO1 expression was significantly positively correlated with the degree of renal tubular injury in renal tissues from LN patients. Using in vitro HK-2 and TCMK-1 cells as well as an in vivo MRL/lpr mouse model, we confirmed that knockdown of CDO1 alleviated renal tubular epithelial cell injury and lipid deposition. Mechanistic studies revealed that CDO1 inhibits lipid metabolism by negatively regulating the expression of ACSM3; notably, downregulation of ACSM3 reversed the ameliorative effects of CDO1 knockdown on lipid deposition and cellular injury. Further investigation demonstrated that ACSM3 deficiency mediates lipid deposition by inducing mitochondrial morphological abnormalities and dysfunction. In summary, this study uncovers a novel mechanism by which the CDO1–ACSM3 axis mediates renal tubular lipid deposition and injury in LN through the regulation of mitochondrial function, offering a potential therapeutic target for this disease.
Open AccessThe CDO1–ACSM3 Axis Mediates Renal Tubule Lipid Deposition and Injury by Causing Mitochondrial Dysfunction in Lupus Nephritis
Renal tubular injury plays a critical role in the progression of lupus nephritis (LN); however, the underlying mechanisms remain poorly understood. In this study, we found that CDO1 expression was significantly positively correlated with the degree of renal tubular injury in renal tissues from LN patients. Using in vitro HK-2 and TCMK-1 cells as well as an in vivo MRL/lpr mouse model, we confirmed that knockdown of CDO1 alleviated renal tubular epithelial cell injury and lipid deposition. Mechanistic studies revealed that CDO1 inhibits lipid metabolism by negatively regulating the expression of ACSM3; notably, downregulation of ACSM3 reversed the ameliorative effects of CDO1 knockdown on lipid deposition and cellular injury. Further investigation demonstrated that ACSM3 deficiency mediates lipid deposition by inducing mitochondrial morphological abnormalities and dysfunction. In summary, this study uncovers a novel mechanism by which the CDO1–ACSM3 axis mediates renal tubular lipid deposition and injury in LN through the regulation of mitochondrial function, offering a potential therapeutic target for this disease.
- Open Access
- 11 June 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 161, 115059
HERC5 induces podocyte injury in LN by mediated IRF3 ISGylation to promote the production and overactivation of IFN-β in podocytes
- 11 June 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 161, 115059
Open AccessHERC5 induces podocyte injury in LN by mediated IRF3 ISGylation to promote the production and overactivation of IFN-β in podocytes